Edition:
United Kingdom

SAGE Therapeutics Inc (SAGE.OQ)

SAGE.OQ on NASDAQ Stock Exchange Global Market

153.20USD
5:39pm GMT
Change (% chg)

$-10.66 (-6.51%)
Prev Close
$163.86
Open
$167.33
Day's High
$171.36
Day's Low
$152.31
Volume
159,845
Avg. Vol
295,986
52-wk High
$195.97
52-wk Low
$59.59

Chart for

About

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and... (more)

Overall

Beta: --
Market Cap(Mil.): $2,399.97
Shares Outstanding(Mil.): 37.44
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Sage Therapeutics Qtrly Net Loss Per Share $1.75

* SAGE THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATE

11:58am GMT

BRIEF-Sage Therapeutics Prices Public Offering Of 3.5 Mln Shares At $164/Share

* PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 3.5 MILLION SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $164.00 PER SHARE​ Source text for Eikon: Further company coverage:

09 Feb 2018

BRIEF-Sage Therapeutics Announces Proposed Public Offering Of Common Stock

* SAGE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

07 Feb 2018

BRIEF-Sage Therapeutics Receives FDA Breakthrough Therapy Designation For Sage-217

* SAGE THERAPEUTICS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR SAGE-217 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

07 Feb 2018

BRIEF-Sage Therapeutics Says Sage-217 Met Primary Endpoint Of Improved Sleep Efficiency In Phase 1/2 Study

* SAGE THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PLACEBO-CONTROLLED TRIAL IN A MODEL OF INSOMNIA DEMONSTRATING ACTIVITY ON SLEEP PARAMETERS AND SUPPORTING DEVELOPMENT OF SAGE-217 AS POTENTIAL TREATMENT FOR SLEEP DISORDERS

31 Jan 2018

Sage shares surge as depression drug succeeds in mid-stage trial

Drug developer Sage Therapeutics Inc's shares soared as much as 85 percent to a record high on Thursday after its experimental drug to reduce the symptoms of depression succeeded in a mid-stage trial.

07 Dec 2017

UPDATE 3-Sage shares surge as depression drug succeeds in mid-stage trial

* Shares surge as much as 85 pct (Adds details on drug's mechanism, analyst comment, updates shares)

07 Dec 2017

Sage's depression drug succeeds in mid-stage study

Dec 7 Sage Therapeutics Inc said on Thursday its drug to treat patients with moderate to severe depression met the main goal in a mid-stage study.

07 Dec 2017

BRIEF-Sage Therapeutics prices public offering of 3.53 mln common shares at $85/share

* SAYS PUBLIC OFFERING OF 3.53 MILLION COMMON SHARES PRICED AT $85.00PER SHARE Source text for Eikon: Further company coverage:

15 Nov 2017

BRIEF-Sage Therapeutics announces proposed public offering of common stock

* Sage Therapeutics announces proposed public offering of common stock

13 Nov 2017

Earnings vs. Estimates